Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 13/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290851 | 0.90 | CTSK (0.37) | CTSKCTSSCA12CA1CA2 | |
| SCHEMBL6889561 | 0.87 | CA12 (0.37) | CTSKCTSSCA12CA1CA2 | |
| SCHEMBL7260635 | 0.86 | TDP1 (0.36) | TDP1CTSKCTSSCA12CA1 | |
| SCHEMBL3288375 | 0.84 | TDP1 (0.36) | TDP1CTSKCTSS | |
| SCHEMBL3293189 | 0.80 | CAPN1 (0.39) | TDP1CTSKCTSSCA12CA1 | |
| SCHEMBL3290839 | 0.76 | CTSK (0.35) | CTSKCTSS | |
| SCHEMBL4519161 | 0.74 | CTSK (0.32) | CTSKCTSS | |
| SCHEMBL3289720 | 0.73 | CA12 (0.31) | TDP1CA12CA1CA2CA14 | |
| SCHEMBL13469276 | 0.73 | TDP1 (0.49) | TDP1CTSKCTSSCA1CA2 | |
| SCHEMBL6889549 | 0.73 | CTSK (0.33) | CTSKCTSSCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7531676-B2 | Lipids | CELLTECH R & D LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-20060148761-A1 | Lipids | CELLTECH R & D LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-20040024220-A1 | Lipids | CELLTECH R & D LIMITED | 2004-02-05 | — | — | US | disclosed |
| US-6583301-B1 | Bipolar; form complexes with polyanions; delivering bioactive substances such as nucleic acids to cells in vitro and in vivo | CELLTECH R & D LIMITED (GB) | 2003-06-24 | — | — | US | disclosed |
| EP-1204428-A2 | TARGETED LIPID PARTICLES | Celltech R&D Limited (GB) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001012154-A2 | TARGETED LIPID PARTICLES | CELLTECH R&D LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| EP-1070047-A2 | LIPIDS | Celltech Chiroscience Limited (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999052858-A2 | LIPIDS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024220-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | TDP1 1253/4885CTSK 4117/4885CTSS 4139/4885 |
| US-20060148761-A1 | Lipids | PHOSPHO1, FABP7, MBOAT7 | TDP1 1253/4885CTSK 4117/4885CTSS 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.